CITIUS ONCOLOGY INC (CTOR) Stock Price & Overview
NASDAQ:CTOR • US17331Y1091
Current stock price
The current stock price of CTOR is 0.8779 USD. Today CTOR is up by 9.03%. In the past month the price increased by 27.08%. In the past year, price increased by 30.66%.
CTOR Key Statistics
- Market Cap
- 77.501M
- P/E
- N/A
- Fwd P/E
- 2.21
- EPS (TTM)
- -0.31
- Dividend Yield
- N/A
CTOR Stock Performance
CTOR Stock Chart
CTOR Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CTOR. When comparing the yearly performance of all stocks, CTOR turns out to be only a medium performer in the overall market: it outperformed 47.77% of all stocks.
CTOR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CTOR. Both the profitability and financial health of CTOR have multiple concerns.
CTOR Earnings
On February 13, 2026 CTOR reported an EPS of -0.06 and a revenue of 3.94M. The company missed EPS expectations (-198.04% surprise) and missed revenue expectations (-11.66% surprise).
CTOR Forecast & Estimates
7 analysts have analysed CTOR and the average price target is 6.12 USD. This implies a price increase of 597.12% is expected in the next year compared to the current price of 0.8779.
CTOR Groups
Sector & Classification
CTOR Financial Highlights
Over the last trailing twelve months CTOR reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 30.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.49% | ||
| ROE | -40.46% | ||
| Debt/Equity | 0.07 |
CTOR Ownership
CTOR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.05 | 369.653B | ||
| AMGN | AMGEN INC | 15.56 | 188.346B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 171.971B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.65 | 110.812B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.01 | 78.867B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.37 | 42.456B | ||
| INSM | INSMED INC | N/A | 30.821B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.581B | ||
| NTRA | NATERA INC | N/A | 27.795B | ||
| BIIB | BIOGEN INC | 11 | 25.833B | ||
| UTHR | UNITED THERAPEUTICS CORP | 20.13 | 25.444B | ||
| MRNA | MODERNA INC | N/A | 21.686B | ||
| INCY | INCYTE CORP | 12.64 | 18.97B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CTOR
Company Profile
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. The company is headquartered in Cranford, New Jersey. The company went IPO on 2022-10-14. The firm is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. The company is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
Company Info
IPO: 2022-10-14
CITIUS ONCOLOGY INC
11 Commerce Drive, 1St Floor
Cranford NEW JERSEY US
Employees: 0
Phone: 19089676677
CITIUS ONCOLOGY INC / CTOR FAQ
What does CITIUS ONCOLOGY INC do?
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. The company is headquartered in Cranford, New Jersey. The company went IPO on 2022-10-14. The firm is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. The company is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
What is the stock price of CITIUS ONCOLOGY INC today?
The current stock price of CTOR is 0.8779 USD. The price increased by 9.03% in the last trading session.
What is the dividend status of CITIUS ONCOLOGY INC?
CTOR does not pay a dividend.
How is the ChartMill rating for CITIUS ONCOLOGY INC?
CTOR has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is CITIUS ONCOLOGY INC (CTOR) stock traded?
CTOR stock is listed on the Nasdaq exchange.
What is the next earnings date for CTOR stock?
CITIUS ONCOLOGY INC (CTOR) will report earnings on 2026-05-12.
What is the ownership structure of CITIUS ONCOLOGY INC (CTOR)?
You can find the ownership structure of CITIUS ONCOLOGY INC (CTOR) on the Ownership tab.